Tegan Grace

Tegan Grace

Auto-generated profile, based on publicly available information

Tegan Grace

School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
TGTegan Grace
Tegan Grace
JFJoshua Fisher
Joshua Fisher
CWCarol Wang
Carol Wang
SVSarah R Valkenborghs
Sarah R Valkenborghs
RSRoger Smith
Roger Smith
CPCraig E Pennell
Craig E Pennell
Introduction Multiple cohort studies have been established to investigate the impact of early life factors on development and health outcomes. In Australia the majority of these studies were established more than 20 years ago and, although longitudinal in nature, are inherently susceptible to socioeconomic, environmental and cultural influences which change over time. Additionally, rapid leaps in technology have increased our understanding of the complex role of gene–environment interactions in life course health, highlighting the need for new cohort studies with repeated biological sampling and in-depth phenotype data across the first 1000 days of life from conception. Methods and analysis The Newcastle 1000 (NEW1000) Study, based in the regional city of Newcastle, New South Wales, was developed after an extensive consultation process involving 3 years of discussion with key stakeholders and healthcare consumer organisations and seven healthcare consumer workshops. This prospective population-based pregnancy cohort study will recruit 500 families per year for 5 years, providing detailed, longitudinal, multisystem phenotyping, repeated ultrasound measures and serial sample collection to investigate healthcare consumer identified health outcomes of priority. Stage 1 will involve recruitment of pregnant participants and their partners at 14 weeks gestation, with dense phenotype data and biological samples collected at 14, 20, 28 and 36 weeks gestation and serial ultrasound measures at 20, 28, 36 and 40 weeks, with postpartum follow-up at 6 weeks and 6 months. Biological samples will be used for biomarker discovery and sequencing of the genome, transcriptome, epigenome, microbiome and metabolome. Ethics and dissemination Ethics approval was obtained from Hunter New England Local Health District Ethics Committee (2020/ETH02881). Outcomes will be published in peer-reviewed journals, disseminated to participants through the NEW1000 website, presented at scientific conferences, and written reports to local, state and national government bodies and key stakeholders in the healthcare system to inform policy and evidence-based practice.

7 August 2018 in Research in Developmental Disabilities
Verified
Journal Article
Closed access
BHBeth Hands
Beth Hands
PCPaola Chivers
Paola Chivers
TGTegan Grace
Tegan Grace
FMFleur McIntyre
Fleur McIntyre

15 November 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
JFJoshua J Fisher
Joshua J Fisher
TGTegan Grace
Tegan Grace
NCNathan A Castles
Nathan A Castles
EJElizabeth A Jones
Elizabeth A Jones
SDSarah J Delforce
Sarah J Delforce
CPCraig E Pennell
Craig E Pennell
Background: Research in the developmental origins of health and disease provides compelling evidence that adverse events during the first 1000 days of life from conception can impact life course health. Despite many decades of research, we still lack a complete understanding of the mechanisms underlying some of these associations. The Newcastle 1000 Study (NEW1000) is a comprehensive, prospective population-based pregnancy cohort study based in Newcastle, New South Wales, Australia, that will recruit pregnant women and their partners at 11-14 weeks’ gestation, with assessments at 20, 28, and 36 weeks; birth; 6 weeks; and 6 months, in order to provide detailed data about the first 1000 days of life to investigate the developmental origins of noncommunicable diseases. Objective: The study aims to provide a longitudinal multisystem approach to phenotyping, supported by robust clinical data and collection of biological samples in NEW1000. Methods: This manuscript describes in detail the large variety of samples collected in the study and the method of collection, storage, and utility of the samples in the biobank, with a particular focus on incorporation of the samples into emerging and novel large-scale “-omics” platforms, including the genome, microbiome, epigenome, transcriptome, fragmentome, metabolome, proteome, exposome, and cell-free DNA and RNA. Specifically, this manuscript details the methods used to collect, process, and store biological samples, including maternal, paternal, and fetal blood, microbiome (stool, skin, vaginal, oral), urine, saliva, hair, toenail, placenta, colostrum, and breastmilk. Results: Recruitment for the study began in March 2021. As of July 2024, 1040 women and 684 partners were enrolled, with 922 infants born. The NEW1000 biobank contains 24,357 plasma aliquots from ethylenediaminetetraacetic acid (EDTA) tubes, 5284 buffy coat aliquots, 4000 plasma aliquots from lithium heparin tubes, 15,884 blood serum aliquots, 2977 PAX RNA tubes, 26,595 urine sample aliquots, 2280 fecal swabs, 17,687 microbiome swabs, 2356 saliva sample aliquots, 1195 breastmilk sample aliquots, 4007 placental tissue aliquots, 2680 hair samples, and 2193 nail samples. Conclusions: NEW1000 will generate a multigenerational, deeply phenotyped cohort with a comprehensive biobank of samples relevant to a large variety of analyses, including multiple -omics platforms. International Registered Report Identifier (IRRID): DERR1-10.2196/63562

4 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
TGTegan Grace
Tegan Grace
SHSamantha Hoskins
Samantha Hoskins
KPKirsty G Pringle
Kirsty G Pringle
GMGillian Mason
Gillian Mason
MTMelinda Cruz Turner
Melinda Cruz Turner
CPCraig Pennell
Craig Pennell
Objectives Research to develop early screening tools to determine an individual’s risk of developing adult-onset disease is a growing field. Expectant parents may find themselves with an option in the future to undergo screening to determine not only genetic abnormalities in their child but also their risk of developing adult-onset non-communicable diseases (NCD) such as hypertension, obesity or hypercholesterolaemia. To ensure acceptability and feasibility of new screening tools researchers must work in partnership with healthcare consumers to discern consumers’ current understanding and acceptance of these technologies in research and the potential for clinical applications. We sought to engage with healthcare consumers to develop a consensus, using a modified Delphi study design, for the acceptability of (1) screening tools for use within pregnancy that would indicate a child’s risk for developing NCD, and (2) targeted early interventions for those identified at a higher risk of developing NCD using precision medicine approaches. The acceptability of future research design and conduct as well as the implications for implementation into routine healthcare were discussed. In addition, participants were asked to rank the non-communicable diseases they believed were of most importance for precision medicine research focus, in line with recent calls for better involvement of healthcare consumers in setting research questions and defining priority areas. Design A modified two-stage Delphi study design including an in-person consumer workshop (stage 1) and online follow-up survey (stage 2), was used to evaluate consumer consensus for research to develop precision medicine tools for early detection and potential intervention to reduce onset of NCDs. The acceptability of research design and conduct and future implications for the implementation of newly developed tools into routine healthcare was also addressed. Setting and participants We engaged 76 healthcare consumers in 2020, in the Hunter New England Region, New South Wales, Australia. Participants were recruited from existing healthcare consumer organisations, research programmes and healthcare networks through purposeful selection, with a focus on participants having a broad range of experiences and backgrounds to ensure adequate representativeness. Results and conclusions Our findings indicate the majority (98%) of participants in our study believe early screening for risk of NCD in their children was acceptable, provided it was equitable and clear pathways for referral and support were available.

1 July 2026 in Maternal & Child Nutrition
Verified
Journal Article
Open access
PDF file
GCGenette Li Hui Chua
Genette Li Hui Chua
Mitch J DuncanMitch J Duncan
Mitch J Duncan
CCClare Collins
Clare Collins
RTRachael Taylor
Rachael Taylor
KOKee June Ooi
Kee June Ooi
SFSasha Fenton
Sasha Fenton
Poor sleep and suboptimal diet are common during pregnancy and contribute to adverse maternal and infant outcomes. While sleep‐diet associations are documented in general populations, evidence in pregnancy is scarce. This study investigated associations between sleep quality and duration and diet quality and dietary intake among Australian pregnant women. Data from two Australian pregnancy cohorts (Newcastle1000 and ORIGINS; n = 1070) were collected at 18–20 weeks gestation (2017–2024). Sleep was assessed using the Pittsburgh Sleep Quality Index (PSQI), and dietary intake and diet quality using the Australian Eating Survey and Australian Recommended Food Score (ARFS). Generalised linear models examined associations between sleep quality (continuous PSQI score) and sleep duration (< 7 h, 7–9 h, > 9 h) and dietary variables, adjusting for age, income, pre‐pregnancy BMI, mental health, physical activity, and cohort. Participants were aged 32.3 ± 4.3 years; with a pre‐pregnancy BMI of 25.9 ± 5.7 kg/m 2 and 95.3% were English‐speaking. Most participants reported poor sleep quality (72.9%; PSQI global score 6.4 ± 2.8) and suboptimal diet quality (ARFS 35.5 ± 8.9). Poor sleep quality was associated with higher saturated fat intake (Exp(β) = 1.004, 95% CI: 1.000,1.008, p = 0.046). Short sleep duration (< 7 h) was associated with lower diet quality ( β = −2.60, 95% CI: −3.95, −1.25, p < 0.001) and lower fibre intake (Exp(β) = 0.945, 95% CI: 0.900,0.992, p = 0.022). No other significant associations were observed in adjusted models. Poor sleep quality and short sleep duration were associated with less favourable dietary patterns during pregnancy. This highlights the need for further research to inform integrated interventions that consider sleep quality and duration alongside strategies to support healthier eating patterns and improve maternal and infant health outcomes.

24 June 2024 in JMIR Preprints
Verified
Preprint
Open access
JFJoshua J Fisher
Joshua J Fisher
TGTegan Grace
Tegan Grace
NCNathan A Castles
Nathan A Castles
EJElizabeth A Jones
Elizabeth A Jones
SDSarah J Delforce
Sarah J Delforce
CPCraig E Pennell
Craig E Pennell
BACKGROUND Research in the developmental origins of health and disease provides compelling evidence that adverse events during the first 1000 days of life from conception can impact life course health. Despite many decades of research, we still lack a complete understanding of the mechanisms underlying some of these associations. The Newcastle 1000 Study (NEW1000) is a comprehensive, prospective population-based pregnancy cohort study based in Newcastle, New South Wales, Australia, that will recruit pregnant women and their partners at 11-14 weeks’ gestation, with assessments at 20, 28, and 36 weeks; birth; 6 weeks; and 6 months, in order to provide detailed data about the first 1000 days of life to investigate the developmental origins of noncommunicable diseases. OBJECTIVE The study aims to provide a longitudinal multisystem approach to phenotyping, supported by robust clinical data and collection of biological samples in NEW1000. METHODS This manuscript describes in detail the large variety of samples collected in the study and the method of collection, storage, and utility of the samples in the biobank, with a particular focus on incorporation of the samples into emerging and novel large-scale “-omics” platforms, including the genome, microbiome, epigenome, transcriptome, fragmentome, metabolome, proteome, exposome, and cell-free DNA and RNA. Specifically, this manuscript details the methods used to collect, process, and store biological samples, including maternal, paternal, and fetal blood, microbiome (stool, skin, vaginal, oral), urine, saliva, hair, toenail, placenta, colostrum, and breastmilk. RESULTS Recruitment for the study began in March 2021. As of July 2024, 1040 women and 684 partners were enrolled, with 922 infants born. The NEW1000 biobank contains 24,357 plasma aliquots from ethylenediaminetetraacetic acid (EDTA) tubes, 5284 buffy coat aliquots, 4000 plasma aliquots from lithium heparin tubes, 15,884 blood serum aliquots, 2977 PAX RNA tubes, 26,595 urine sample aliquots, 2280 fecal swabs, 17,687 microbiome swabs, 2356 saliva sample aliquots, 1195 breastmilk sample aliquots, 4007 placental tissue aliquots, 2680 hair samples, and 2193 nail samples. CONCLUSIONS NEW1000 will generate a multigenerational, deeply phenotyped cohort with a comprehensive biobank of samples relevant to a large variety of analyses, including multiple -omics platforms. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/63562